Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Apr;70(4):2247–2251. doi: 10.1128/jvi.70.4.2247-2251.1996

Construction and characterization of replication-competent simian immunodeficiency virus vectors that express gamma interferon.

L D Giavedoni 1, T Yilma 1
PMCID: PMC190065  PMID: 8642649

Abstract

We report the construction and characterization of several replication-competent simian immunodeficiency virus (SIV) vectors with a deletion in the viral nef gene (SIV(delta nef)) that express gamma interferon (IFN-gamma). The expression of the cytokine gene was controlled either by the simian virus 40 early promoter or by the SIV 5' long terminal repeat regulatory sequences, utilizing the nef gene splice signals. To enhance the expression of IFN-gamma, the two in-frame nef start codons were mutated without altering the Env amino acid sequence (SIV(HyIFN)). Plasmids containing full-length proviral genomes were used to obtain high-titer stocks of each recombinant virus in cell cultures. Expression of IFN-gamma by SIV(HyIFN) reached levels as high as 10(6) U/ml after 11 days in culture. The IFN-gamma gene was unstable and sustained deletions after serial passage of SIV(delta nef) vectors in CEM-X-174 cells. The degree of instability appears to depend on size and orientation of the insert and the expression of IFN-gamma. Only one virus, SIV(HyIFN), expressed detectable levels of IFN-gamma up to the sixth passage. Prospects for the use of IFN-gamma and other lymphokines to enhance the safety and efficacy of live attenuated vaccines are discussed.

Full Text

The Full Text of this article is available as a PDF (280.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmad S., Lohman B., Marthas M., Giavedoni L., el-Amad Z., Haigwood N. L., Scandella C. J., Gardner M. B., Luciw P. A., Yilma T. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1994 Feb;10(2):195–204. doi: 10.1089/aid.1994.10.195. [DOI] [PubMed] [Google Scholar]
  2. Anderson K. P., Fennie E. H., Yilma T. Enhancement of a secondary antibody response to vesicular stomatitis virus "G" protein by IFN-gamma treatment at primary immunization. J Immunol. 1988 May 15;140(10):3599–3604. [PubMed] [Google Scholar]
  3. Baba T. W., Jeong Y. S., Pennick D., Bronson R., Greene M. F., Ruprecht R. M. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science. 1995 Mar 24;267(5205):1820–1825. doi: 10.1126/science.7892606. [DOI] [PubMed] [Google Scholar]
  4. Chen B. K., Saksela K., Andino R., Baltimore D. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. J Virol. 1994 Feb;68(2):654–660. doi: 10.1128/jvi.68.2.654-660.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Connor R. I., Chen B. K., Choe S., Landau N. R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology. 1995 Feb 1;206(2):935–944. doi: 10.1006/viro.1995.1016. [DOI] [PubMed] [Google Scholar]
  6. Daniel M. D., Kirchhoff F., Czajak S. C., Sehgal P. K., Desrosiers R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992 Dec 18;258(5090):1938–1941. doi: 10.1126/science.1470917. [DOI] [PubMed] [Google Scholar]
  7. Delwart E. L., Buchschacher G. L., Jr, Freed E. O., Panganiban A. T. Analysis of HIV-1 envelope mutants and pseudotyping of replication-defective HIV-1 vectors by genetic complementation. AIDS Res Hum Retroviruses. 1992 Sep;8(9):1669–1677. doi: 10.1089/aid.1992.8.1669. [DOI] [PubMed] [Google Scholar]
  8. Desrosiers R. C. Safety issues facing development of a live-attenuated, multiply deleted HIV-1 vaccine. AIDS Res Hum Retroviruses. 1994 Apr;10(4):331–332. doi: 10.1089/aid.1994.10.331. [DOI] [PubMed] [Google Scholar]
  9. Fan S. X., Turpin J. A., Aronovitz J. R., Meltzer M. S. Interferon-gamma protects primary monocytes against infection with human immunodeficiency virus type 1. J Leukoc Biol. 1994 Sep;56(3):362–368. doi: 10.1002/jlb.56.3.362. [DOI] [PubMed] [Google Scholar]
  10. Flexner C., Hügin A., Moss B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature. 1987 Nov 19;330(6145):259–262. doi: 10.1038/330259a0. [DOI] [PubMed] [Google Scholar]
  11. Gabuzda D. H., Lawrence K., Langhoff E., Terwilliger E., Dorfman T., Haseltine W. A., Sodroski J. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol. 1992 Nov;66(11):6489–6495. doi: 10.1128/jvi.66.11.6489-6495.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Giavedoni L. D., Jones L., Gardner M. B., Gibson H. L., Ng C. T., Barr P. J., Yilma T. Vaccinia virus recombinants expressing chimeric proteins of human immunodeficiency virus and gamma interferon are attenuated for nude mice. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3409–3413. doi: 10.1073/pnas.89.8.3409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Giavedoni L. D., Planelles V., Haigwood N. L., Ahmad S., Kluge J. D., Marthas M. L., Gardner M. B., Luciw P. A., Yilma T. D. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol. 1993 Jan;67(1):577–583. doi: 10.1128/jvi.67.1.577-583.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hartshorn K. L., Neumeyer D., Vogt M. W., Schooley R. T., Hirsch M. S. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. AIDS Res Hum Retroviruses. 1987 Summer;3(2):125–133. doi: 10.1089/aid.1987.3.125. [DOI] [PubMed] [Google Scholar]
  15. He J., Landau N. R. Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor. J Virol. 1995 Jul;69(7):4587–4592. doi: 10.1128/jvi.69.7.4587-4592.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Heagy W., Groopman J., Schindler J., Finberg R. Use of IFN-gamma in patients with AIDS. J Acquir Immune Defic Syndr. 1990;3(6):584–590. [PubMed] [Google Scholar]
  17. Karupiah G., Blanden R. V., Ramshaw I. A. Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection. J Exp Med. 1990 Nov 1;172(5):1495–1503. doi: 10.1084/jem.172.5.1495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kestler H. W., 3rd, Ringler D. J., Mori K., Panicali D. L., Sehgal P. K., Daniel M. D., Desrosiers R. C. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 1991 May 17;65(4):651–662. doi: 10.1016/0092-8674(91)90097-i. [DOI] [PubMed] [Google Scholar]
  19. Kohonen-Corish M. R., King N. J., Woodhams C. E., Ramshaw I. A. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur J Immunol. 1990 Jan;20(1):157–161. doi: 10.1002/eji.1830200123. [DOI] [PubMed] [Google Scholar]
  20. Maheshwari R. K., Srikantan V., Bhartiya D., Puri S. K., Dutta G. P., Dhawan B. N. Effects of interferon in malaria infection. Immunol Lett. 1990 Aug;25(1-3):53–57. doi: 10.1016/0165-2478(90)90091-4. [DOI] [PubMed] [Google Scholar]
  21. Morrill J. C., Czarniecki C. W., Peters C. J. Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey. J Interferon Res. 1991 Oct;11(5):297–304. doi: 10.1089/jir.1991.11.297. [DOI] [PubMed] [Google Scholar]
  22. Murphey-Corb M., Martin L. N., Davison-Fairburn B., Montelaro R. C., Miller M., West M., Ohkawa S., Baskin G. B., Zhang J. Y., Putney S. D. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 1989 Dec 8;246(4935):1293–1297. doi: 10.1126/science.2555923. [DOI] [PubMed] [Google Scholar]
  23. Nagy K., Young M., Baboonian C., Merson J., Whittle P., Oroszlan S. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase. J Virol. 1994 Feb;68(2):757–765. doi: 10.1128/jvi.68.2.757-765.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Page K. A., Landau N. R., Littman D. R. Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol. 1990 Nov;64(11):5270–5276. doi: 10.1128/jvi.64.11.5270-5276.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ramshaw I. A., Andrew M. E., Phillips S. M., Boyle D. B., Coupar B. E. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature. 1987 Oct 8;329(6139):545–546. doi: 10.1038/329545a0. [DOI] [PubMed] [Google Scholar]
  26. Schijns V. E., Borman T. H., Schellekens H., Horzinek M. C. Antiviral activity of recombinant rat interferon gamma in immunologically impaired and immunosuppressed rats. J Gen Virol. 1988 Aug;69(Pt 8):1979–1985. doi: 10.1099/0022-1317-69-8-1979. [DOI] [PubMed] [Google Scholar]
  27. Wang C. T., Barklis E. Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J Virol. 1993 Jul;67(7):4264–4273. doi: 10.1128/jvi.67.7.4264-4273.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES